Respiratory syncytial virus, commonly known as RSV, is typically a seasonal virus that causes upper respiratory (nasal drainage, nasal congestion) and lower respiratory (coughing, wheezing, difficulty breathing) symptoms. The disease is generally referred to as “bronchiolitis,” which is defined as inflammation of the lower airways. Bronchiolitis can result from many other viruses apart from RSV.
In our region, RSV season typically lasts from October to late April or early May. Last year, the 2022 RSV surge was severe and filled children’s hospitals with ill infants and children. There are many theories as to the cause of the severity, with one likely cause being decreased RSV immunity in the general population from isolation practices such as social distancing and mask usage during the COVID-19 pandemic.

When to expect RSV
According to the U.S. Centers for Disease Control and Prevention’s RSV surveillance map for last year’s surge, West Virginia and Pennsylvania saw widespread RSV infections beginning in late September/early October, about one month later than southern states, like Georgia and Tennessee. The same map for this year shows an increase in RSV positivity in Georgia starting around mid-August.
Most health care providers believe that we will soon begin seeing more positive RSV tests and ill infants and toddlers. However, it is not clear that this season will be as severe as last year.
RSV prevention and care
RSV is a virus that is spread primarily through direct contact. Practicing good hand hygiene using soap and water (20 seconds of washing) or alcohol-based hand sanitizer provides the best protection for you and your family. RSV can survive for several hours on our hands and surfaces after wiping noses, coughing or sneezing.
If you or your child are exposed, the incubation period — the amount of time between exposure to the virus and the appearance of symptoms — usually ranges from four to six days. Symptoms from RSV infection typically last anywhere from seven to 14 days, with the peak of symptoms on day five and gradual improvement thereafter.
As there is not yet a cure or effective treatment for RSV, efforts should be focused on providing symptom relief, such as ensuring hydration with good oral intake, fever control with acetaminophen or ibuprofen, and nasal suctioning.
Since babies prefer to breathe through their noses, clearing their nostrils with nasal suctioning prior to bottle feeding will give your baby the best chance of eating well. Avoid administering over-the-counter cough suppressants, as our cough allows us to clear mucus from our airways.
RSV warning signs
If you notice that your child has difficulty breathing — breathing too fast, flaring of the nostrils when breathing, showing retractions (indentation of skin between ribs, under rib cage, above the sternum), appearing cyanotic (blueness of the face or body indicating inadequate oxygen levels in the body), apnea (long pauses in breathing) or is becoming dehydrated — you should seek medical care immediately.
Risk factors for more severe RSV infection can include infants less than 6 months of age, premature infants, children with chronic lung or heart disease, patients exposed to secondhand smoke and patients with immune system deficiency.
New treatments
This year, a new drug is approved to provide immunity to RSV. Nirsevimab is in a drug class referred to as monoclonal antibodies, which is designed to provide antibodies against the RSV fusion protein to block the virus from entering our cells and causing disease. This form of immunity is referred to as “passive immunity,” where the necessary antibodies to fight bacteria and viruses are not made by the body but injected into the body.
In March, a study looking at new drugs, including Arexvy (approved for ages 60 and up), and published in The Lancet medical journal showed decreased severity of RSV infections and a decrease in hospital admissions for RSV infections.
The FDA has approved this medication for all infants less than 8 months of age during RSV season. Some infants at high risk for severe disease are approved for a 2nd dose next year.
It is hoped that this new medication will be a game-changer as we battle RSV. I will recommend it for my patients who are eligible. For more information about nirsevimab or about the recently approved RSV vaccine for adults, consult your health care provider.
The CDC on Monday issued an alert that nirsevimab is currently in short supply in the U.S., and therefore recommended the 100 mg doses be given to those infants at highest risk for a severe case of the disease.
RSV is the leading cause of hospitalizations in children less than 1 year of age. While there are no effective antiviral medications to treat it, providing supportive care with nasal suctioning, ensuring hydration, and administering anti-fever medications will help to keep your child well.
Watch for the warning signs of severe disease, and, if you see them, seek medical care immediately. Be on the watch for new treatments, including the ones mentioned here. Your health care provider will help you make the best decision for you and your family.
Jeff Lancaster is associate chief medical officer and chief of pediatric hospital medicine at WVU Medicine Children’s.






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.